Powered by
3D Signatures announces initiation of Hodgkin's lymphoma validation program
Feb 23, 2017 - Marketline Newswire

3D Signatures Inc. has announced the initiation of validation program for its Hodgkin's lymphoma, or HL, test, or Telo-HL.

Telo-HL is powered by the Company's proprietary TeloView software platform. The purpose of Telo-HL is to stratify HL patients at the point of diagnosis into non-relapsing and relapsing patients so that relapsing patients may be considered for alternative treatments to standard chemotherapy at the beginning of their treatment process. There is currently no biomarker

Sign up for unrestricted access to 200+ subscription services.
Already have an account? Click here to login.

RelSci News & Alerts gets you:

  • 10 free articles a month from top subscription outlets like the Financial Times, New York Times, and Washington Post
  • Competitive business intelligence through daily data updates
  • Custom feeds on target high-value individuals, companies, industries, and topics delivered straight to your inbox